Cargando…

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

BACKGROUND: Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidylinositol 3-kinase inhibitor, used in combination with ima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pantaleo, Maria A., Heinrich, Michael C., Italiano, Antoine, Valverde, Claudia, Schöffski, Patrick, Grignani, Giovanni, Reyners, Anna K. L., Bauer, Sebastian, Reichardt, Peter, Stark, Daniel, Berhanu, Ghimja, Brandt, Ulrike, Stefanelli, Tommaso, Gelderblom, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078016/ https://www.ncbi.nlm.nih.gov/pubmed/35524239 http://dx.doi.org/10.1186/s12885-022-09610-4

Ejemplares similares

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022)

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
por: Bauer, S, et al.
Publicado: (2014)

Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)

Alpelisib for breast cancer
Publicado: (2022)

Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial
por: Schlemmer, M, et al.
Publicado: (2011)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021)

Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice
por: Macioszek, Szymon, et al.
Publicado: (2023)

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
por: Benjamin, Robert S., et al.
Publicado: (2010)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)
por: Cappello, Giovanni, et al.
Publicado: (2023)

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014)

Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge
por: Leung, Mova, et al.
Publicado: (2022)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

(18)F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors
por: Stefanelli, Antonella, et al.
Publicado: (2011)

Alpelisib-Induced Diabetic Ketoacidosis- A Case Report
por: Rodriguez, Lisette Patricia, et al.
Publicado: (2021)

A Case of Diabetic Keto Acidosis From Alpelisib
por: Thumma, Soumya P, et al.
Publicado: (2021)

Alpelisib-Induced Hyperglycemia- A Small Case Series
por: Ekanayake, Preethika Subashini, et al.
Publicado: (2021)

Case report: Alpelisib-induced Stevens–Johnson syndrome
por: Kurian, Christine Jane, et al.
Publicado: (2022)

Bilateral Panuveitis and Exudative Retinal Detachments Associated with Alpelisib
por: Chong, Yu Jeat, et al.
Publicado: (2022)

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions
por: Schutte, Tim, et al.
Publicado: (2023)

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
por: Wagner, A. J., et al.
Publicado: (2017)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
por: Schöffski, Patrick, et al.
Publicado: (2022)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs
por: Amirnasr, Azadeh, et al.
Publicado: (2019)

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy
por: Vassos, Nikolaos, et al.
Publicado: (2021)

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
por: Bouché, Olivier, et al.
Publicado: (2018)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
por: Fugere, Tyler, et al.
Publicado: (2021)

A multidisciplinary approach to optimizing care of patients treated with alpelisib
por: Rugo, Hope S., et al.
Publicado: (2021)

RF07 | PSUN359 Alpelisib-induced Diabetic Ketoacidosis
por: Majumdar, Sachin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_scdi5rvpmem8ruia3n8rakp2qp